ES2775425T3 - Procedimiento de tratamiento del síndrome de Prader-Willi - Google Patents
Procedimiento de tratamiento del síndrome de Prader-Willi Download PDFInfo
- Publication number
- ES2775425T3 ES2775425T3 ES15772107T ES15772107T ES2775425T3 ES 2775425 T3 ES2775425 T3 ES 2775425T3 ES 15772107 T ES15772107 T ES 15772107T ES 15772107 T ES15772107 T ES 15772107T ES 2775425 T3 ES2775425 T3 ES 2775425T3
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- receptor agonist
- oxytocin receptor
- selective oxytocin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C[C@@](C(C)=O)NC(CC*)=O Chemical compound C[C@@](C(C)=O)NC(CC*)=O 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462052957P | 2014-09-19 | 2014-09-19 | |
| PCT/US2015/049911 WO2016044131A1 (en) | 2014-09-19 | 2015-09-14 | Method of treating prader-willi syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2775425T3 true ES2775425T3 (es) | 2020-07-27 |
Family
ID=54238564
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15772107T Active ES2775425T3 (es) | 2014-09-19 | 2015-09-14 | Procedimiento de tratamiento del síndrome de Prader-Willi |
| ES19216650T Active ES2970059T3 (es) | 2014-09-19 | 2015-09-14 | Método de tratamiento del síndrome de Prader-Willi |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19216650T Active ES2970059T3 (es) | 2014-09-19 | 2015-09-14 | Método de tratamiento del síndrome de Prader-Willi |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10441627B2 (enExample) |
| EP (2) | EP3666258B1 (enExample) |
| JP (3) | JP6599447B2 (enExample) |
| CN (2) | CN106714819A (enExample) |
| CA (1) | CA2957224A1 (enExample) |
| DK (1) | DK3666258T3 (enExample) |
| ES (2) | ES2775425T3 (enExample) |
| FI (1) | FI3666258T3 (enExample) |
| HR (1) | HRP20240166T1 (enExample) |
| HU (1) | HUE065829T2 (enExample) |
| LT (1) | LT3666258T (enExample) |
| PL (1) | PL3666258T3 (enExample) |
| PT (1) | PT3666258T (enExample) |
| RS (1) | RS65144B1 (enExample) |
| SI (1) | SI3666258T1 (enExample) |
| WO (1) | WO2016044131A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106714819A (zh) * | 2014-09-19 | 2017-05-24 | 辉凌公司 | 治疗普拉德‑威利综合征的方法 |
| WO2019032946A1 (en) | 2017-08-11 | 2019-02-14 | Ferring B.V. | PROCESS FOR PRODUCING OXYTOCIN |
| BR112020001832A2 (pt) | 2017-08-11 | 2020-07-28 | Ferring B.V. | método de produção de uma composição farmacêuti-ca |
| US10736894B2 (en) | 2018-02-15 | 2020-08-11 | Ovid Therapeutics Inc. | Methods of treating developmental syndromes with PDE10A inhibitors |
| CA3112190A1 (en) | 2018-09-20 | 2020-03-26 | Levo Therapeutics, Inc. | Carbetocin drug product and process for preparing same |
| CA3112185C (en) | 2018-09-20 | 2025-10-07 | Acadia Pharmaceuticals Inc. | STABLE INTRANASAL FORMULATIONS OF CARBETOCINE |
| CA3205469A1 (en) * | 2020-12-18 | 2022-06-23 | The General Hospital Corporation | Probiotics compositions and method of using the same to enhance growth and social function in children |
| JP2024511199A (ja) * | 2021-03-26 | 2024-03-12 | オーティーフォービー | 嚥下障害の治療 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7544662B2 (en) | 1993-06-17 | 2009-06-09 | Carle Development Foundation | Polypeptides useful for appetite suppression |
| US6894026B1 (en) | 2000-01-11 | 2005-05-17 | Atossa Healthcare, Inc. | Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders |
| US20070032410A1 (en) | 2000-01-11 | 2007-02-08 | Atossa Healthcare, Inc. | Compositions and methods for the treatment of psychiatric disorders |
| US9023793B2 (en) | 2006-09-29 | 2015-05-05 | Retrophin, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| CA2689476C (en) | 2007-06-07 | 2014-08-05 | Nastech Pharmaceutical Company Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| JP2010538991A (ja) | 2007-09-11 | 2010-12-16 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | 治療剤としてのｓｆｌｌｒ−ｏｈおよびムラミルジペプチドの使用 |
| JP2010539028A (ja) | 2007-09-11 | 2010-12-16 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | 治療剤としてのメラニン凝集ホルモンおよびＭｅｔ−エンケファリンの使用 |
| WO2009033820A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| WO2009033768A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| KR101558404B1 (ko) * | 2008-03-31 | 2015-10-08 | 훼링 비.브이. | 옥시토신 유사체 |
| EP2317845A4 (en) | 2008-07-18 | 2011-11-09 | Zafgen Inc | METHOD FOR TREATING AN OVERWEIGHT OR FATABLE PERSON |
| TWI463990B (zh) * | 2009-09-21 | 2014-12-11 | Ferring Bv | 催產素受體促進劑 |
| US20120108510A1 (en) | 2010-05-20 | 2012-05-03 | Emory University | Methods of improving behavioral therapies |
| US8853158B2 (en) | 2010-05-25 | 2014-10-07 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Methods for the treatment of a feeding disorder with onset during neonate development using an agonist of the oxytocin receptor |
| JO3400B1 (ar) * | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
| WO2012149472A2 (en) | 2011-04-27 | 2012-11-01 | Ignite Institute For Individualized Health | Methods, compositions, and kits for treating and preventing neurological conditions |
| MY176398A (en) | 2012-12-21 | 2020-08-05 | Hoffmann La Roche | Peptides as oxytocin agonists |
| CA2898015A1 (en) | 2013-01-17 | 2014-07-24 | F. Hoffmann-La Roche Ag | Oxytocin receptor agonists for the treatment of cns diseases |
| CN106414479B (zh) | 2014-06-03 | 2021-08-03 | 豪夫迈·罗氏有限公司 | 作为催产素激动剂的肽 |
| CR20160562A (es) | 2014-06-06 | 2017-01-06 | Hoffmann La Roche | Péptidos como agonistas de la oxitocina |
| PL3177635T3 (pl) | 2014-08-07 | 2019-02-28 | F. Hoffmann-La Roche Ag | Sposoby wytwarzania analogów oksytocyny |
| CN106714819A (zh) | 2014-09-19 | 2017-05-24 | 辉凌公司 | 治疗普拉德‑威利综合征的方法 |
-
2015
- 2015-09-14 CN CN201580049147.2A patent/CN106714819A/zh active Pending
- 2015-09-14 ES ES15772107T patent/ES2775425T3/es active Active
- 2015-09-14 HR HRP20240166TT patent/HRP20240166T1/hr unknown
- 2015-09-14 RS RS20240134A patent/RS65144B1/sr unknown
- 2015-09-14 US US15/510,781 patent/US10441627B2/en active Active
- 2015-09-14 PL PL19216650.2T patent/PL3666258T3/pl unknown
- 2015-09-14 PT PT192166502T patent/PT3666258T/pt unknown
- 2015-09-14 ES ES19216650T patent/ES2970059T3/es active Active
- 2015-09-14 WO PCT/US2015/049911 patent/WO2016044131A1/en not_active Ceased
- 2015-09-14 SI SI201531990T patent/SI3666258T1/sl unknown
- 2015-09-14 JP JP2017515228A patent/JP6599447B2/ja active Active
- 2015-09-14 FI FIEP19216650.2T patent/FI3666258T3/fi active
- 2015-09-14 DK DK19216650.2T patent/DK3666258T3/da active
- 2015-09-14 CN CN202110278199.4A patent/CN112773765A/zh active Pending
- 2015-09-14 EP EP19216650.2A patent/EP3666258B1/en active Active
- 2015-09-14 HU HUE19216650A patent/HUE065829T2/hu unknown
- 2015-09-14 LT LTEP19216650.2T patent/LT3666258T/lt unknown
- 2015-09-14 EP EP15772107.7A patent/EP3193907B1/en active Active
- 2015-09-14 CA CA2957224A patent/CA2957224A1/en active Pending
-
2019
- 2019-10-02 JP JP2019181930A patent/JP6921154B2/ja active Active
- 2019-10-03 US US16/592,632 patent/US20200129584A1/en not_active Abandoned
-
2021
- 2021-03-15 JP JP2021041334A patent/JP2021098745A/ja active Pending
-
2022
- 2022-11-18 US US18/057,065 patent/US20240082344A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020019790A (ja) | 2020-02-06 |
| JP2021098745A (ja) | 2021-07-01 |
| EP3666258B1 (en) | 2023-11-15 |
| US20240082344A1 (en) | 2024-03-14 |
| HUE065829T2 (hu) | 2024-06-28 |
| PL3666258T3 (pl) | 2024-04-08 |
| EP3666258A1 (en) | 2020-06-17 |
| FI3666258T3 (fi) | 2024-02-09 |
| PT3666258T (pt) | 2024-02-01 |
| HRP20240166T1 (hr) | 2024-04-26 |
| US20200129584A1 (en) | 2020-04-30 |
| EP3193907B1 (en) | 2020-01-01 |
| JP2017532316A (ja) | 2017-11-02 |
| WO2016044131A1 (en) | 2016-03-24 |
| CN112773765A (zh) | 2021-05-11 |
| DK3666258T3 (da) | 2024-02-05 |
| JP6599447B2 (ja) | 2019-10-30 |
| ES2970059T3 (es) | 2024-05-24 |
| RS65144B1 (sr) | 2024-02-29 |
| EP3193907A1 (en) | 2017-07-26 |
| JP6921154B2 (ja) | 2021-08-18 |
| LT3666258T (lt) | 2024-01-10 |
| SI3666258T1 (sl) | 2024-04-30 |
| US20170326200A1 (en) | 2017-11-16 |
| US10441627B2 (en) | 2019-10-15 |
| CA2957224A1 (en) | 2016-03-24 |
| CN106714819A (zh) | 2017-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2775425T3 (es) | Procedimiento de tratamiento del síndrome de Prader-Willi | |
| US20240382436A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| CN104869993B (zh) | 治疗阿尔茨海默病及相关疾病的组合疗法 | |
| MX2014010939A (es) | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento. | |
| JP2017081930A (ja) | ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 | |
| US20220280450A1 (en) | Prevention and treatment of coronavirus and related respiratory infections | |
| AU2016203771A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| US10512637B2 (en) | Use of inhibitor of cystine-glutamate transporter | |
| US11730769B2 (en) | Compositions and methods for Williams Syndrome (WS) therapy | |
| ES3041320T3 (en) | Ecopipam for treatment of tourettes syndrome | |
| BR112021001328A2 (pt) | composições de licopeno e métodos para proteger a pele contra a radiação ultravioleta | |
| JP2025502098A (ja) | うつ病の治療のための組成物及び方法 | |
| JP2014528458A (ja) | 鼻炎の治療 | |
| AU2013203567A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| US8680145B1 (en) | Compositions and methods for treatment of fear of medical procedures | |
| HK40069995A (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| CN104257658B (zh) | 青藤碱在制备治疗慢性疼痛伴抑郁行为药物中的应用 | |
| AU2013201492A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| CN104257658A (zh) | 青藤碱在制备治疗慢性疼痛伴抑郁行为药物中的应用 |